The study found that SLC25A32 inhibition resulted in anti-proliferative effects on certain tumor cell lines, potentially by increasing reactive oxygen species. Treatment with riboflavin and glutathione rescued cancer cell proliferation upon SLC25A32 down-regulation.
The study demonstrates that MLN4924 treatment induces DNA damage and accumulates cells in S phase, enhancing sensitivity when combined with cisplatin. In vivo results show reduced tumor growth in a NOD-SCID mouse xenograft model treated with MLN4924 alone or in combination with cisplatin.
A randomized, double-blind trial compared the safety and efficacy of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma. F14512 demonstrated significant antitumor activity and clinical benefits, particularly in P-glycoprotein overexpressing lymphomas.
Research found that pre-treatment with empty SV40 capsids increased survival rates from zero to 75% in severe rat sepsis models. The underlying mechanism involves the up-regulation of Hsp/c70 and induction of the PI3K/Akt survival pathway.
This study found that the addition of nimotuzumab to weekly cisplatin-radiation significantly improves outcomes, including overall survival, in locally advanced head and neck cancer patients with HPV negative oropharyngeal cancers. The study compared these outcomes with a control group receiving only cisplatin-radiation.
Researchers found that tumor-derived ANGPTL2 stimulates lung epithelial cells, promoting primary tumor-induced neutrophil recruitment and pre-metastatic niche formation. Targeting ANGPTL2 signaling reduced metastatic load in lungs.
Researchers found niche mutations to have higher mortality than EGFR, but similar mortality to KRAS mutations. Next-generation sequencing helps identify a large panel of mutations for precise treatment selection.
Researchers found that Clostridium perfringens enterotoxin induces CLDN4 nuclear translocation, enhancing epithelial-mesenchymal transition, stemness, and invasive ability in oral squamous cell carcinoma cells. The complex of YAP1, CLDN4, and zona occludens-2 was formed by CPE treatment, suppressing YAP1 phosphorylation and activating it.
Intratumoral SD-101 injection complements low-dose cyclophosphamide in boosting innate immunity and driving potent T cell-mediated anti-tumor responses. This combination therapy improves efficacy against non-injected tumors and long-term survival, even in large tumors.
Researchers developed a novel anti-CEACAM antibody for fluorescence visualization of colorectal tumors and metastases. The antibody targets multiple CEACAMs, which can lead to improved detection of tumor margins and metastases with variable expression of CEA.
Researchers analyzed DNA data from African American and Caucasian American men with prostate cancer, finding lower frequencies of pathogenic/likely alterations in 14 well-characterized DNA repair genes among African Americans. The study suggests a higher risk for germline BRCA mutations but lower risks for non-BRCA mutations
Researchers identified novel PMEPA1-e isoform and characterized its biological functions in prostate cancer. The study found that the methylation of PMEPA1 gene promoter accounts for silencing of PMEPA1 in prostate cancer cells.
Researchers analyzed the virome of HPV-positive tonsil squamous cell carcinoma and neck metastasis, finding correlations between specific viruses and clinical outcomes. The study suggests that certain viral signatures may impact tumor biology and behavior, offering potential avenues for future research and treatment.
Researchers found that AEZS-108 upregulates the tumor suppressor gene MASPIN, inhibiting cell proliferation and inducing apoptosis in LHRH receptor-positive uveal melanoma cells. The study suggests that targeted cytotoxic LHRH analogs like AEZS-108 could serve as an effective treatment for patients with this disease.
A study found that APLN overexpression correlates with worsened prognosis in ovarian cancer patients treated with bevacizumab. The researchers also identified a distinct gene signature associated with resistance development, paving the way for new treatment strategies.
The study reveals that EGFR overexpression is associated with lower expression of multiple proliferation genes, leading to replication stress and decreased survival. Interestingly, certain proteins like CLPTM1L and PBXIP1 are upregulated in EGFR-activated cases, but this does not promote increased proliferation.
Research on NOTCH1 mutations in OSCC reveals tumour suppressive function through ETV7-mediated suppression of SERPINE1. Overexpression of NOTCH1 intracellular domain promotes cell adhesion and differentiation.
Researchers established B6CaP, a prostate-derived tumor line that frequently metastasizes to bones and grows in an immunocompetent host, overcoming limitations of previous models. This model is useful for studying mechanisms of bone metastasis and tumor immune response.
Research reveals that inhibiting Mcl-1 protein can induce apoptosis in estrogen receptor-positive breast cancer cells, suggesting a potential therapeutic strategy for this type of cancer. The study also found that combining Mcl-1 inhibition with ABT-263 increased cell death in ER+ breast cancer cells.
The study evaluates the safety of conditionally immortalized proximal tubule epithelial cells for bioartificial kidney application, demonstrating lack of oncogenic properties and tumorigenic capacity. These cells show promise for clinical application as cell-based renal replacement therapy.
The study found that API-5 is overexpressed in chemoresistant TNBC, associated with increased micro-vessel density and enhanced cell survival. A peptide targeting API-5 shows promise as an innovative treatment option for this aggressive cancer type.
Researchers analyzed pleural effusion fluid from patients with non-small cell lung cancer and malignant mesothelioma, discovering unique cytokine profiles that may influence the tumor environment. The study suggests harnessing the local pleural immune environment could lead to improved treatment outcomes.
A research team found that consuming cholera toxin B stimulates health-protective immune responses that counteract age-associated obesity. The study used animal models and found that the toxin helped restore immune homeostasis and reduce inflammation, leading to leaner physiques and improved health outcomes.
Researchers identify a hyperploid salvage survival pathway in high-grade serous carcinoma cell line models that bypasses apoptosis and emerges as viable large hyperploid cells. This pathway may contribute to acquired resistance and genomic diversity of recovering tumor cells.
Researchers found that API-5 was overexpressed in endothelial cells of patients with chemoresistant TNBC, associated with increased micro-vessel density. API-5 promotes cell survival and cancer growth by inhibiting apoptosis.
Researchers analyzed pleural effusions from NSCLC patients, mesothelioma, and benign cases, identifying distinct cytokine levels that may influence tumor growth and immune response. The study suggests modifying the local pleural immune environment with antibody-based therapeutics could enhance anti-tumor effects.
Researchers analyzed BTB and BBB changes in NSCLC brain metastasis over time, revealing key changes including loss of aquaporin-4 and zona occludens-1. These findings provide a comprehensive analysis of the transition of the blood-brain barrier to the blood-tumor barrier.
Research found that KLK6 overexpression induces HMGA2 expression in colon cancer cells, contributing to CRC progression and metastasis. High KLK6 scores were linked to disease recurrence, suggesting its potential role as a biomarker.
The assay has a clinically relevant 5-day turnaround time and can be conducted on as little as 20 ng genomic DNA. It requires minimum input of tumor DNA without the need for matched normal and is histology agnostic, addressing pre-analytical variability.
Researchers identified high levels of circularized E7 RNA as a positive prognostic marker in anal squamous cell carcinoma (ASCC). The study suggests that circ E7 may play a role in HPV-driven cancers, including head and neck squamous cell carcinomas.
The study found that all tested tyrosine kinase inhibitors increased COX-2 expression in at least one of the tested cell lines in vitro. Fluorocoxib A uptake correlated with COX-2 expression detected by immunohistochemistry and Western blot analysis in xenografts in vivo.
Quinacrine repurposed with cisplatin synergizes to reduce cancer growth, increasing median time to tumor volume by 12 days; enhances apoptosis and inhibits autophagy in HNSCC cells.
The RESILIENT trial found disease control in 114 out of 126 patients evaluable per protocol and progression-free survival. The study suggests that label-agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefits for patients with relapsed refractory metastatic malignancies.
Researchers found that mutation and loss of TSC1 leads to decreased sensitivity to Hsp90 inhibitors, causing hypoacetylation of Hsp90. Co-targeting HDACs may restore Hsp90 acetylation and sensitivity in bladder cancer patients with TSC1 mutations.
The 2019 Nobel Prize has been awarded to William G. Kaelin Jr, Gregg L. Semenza, and Sir Peter J. Ratcliffe for their discoveries of how cells sense and adapt to oxygen availability. This mechanism has far-reaching implications for treating conditions like cancer, heart attack, and stroke.
Researchers have identified FGFR3 mutations in a subset of meningioma patients with favorable prognoses, suggesting potential for targeted therapy. These mutations may enhance diagnostic accuracy and clinical decision-making.
Targeting HDAC2 with romidepsin inhibits MDM2 expression and promotes apoptosis in dedifferentiated liposarcoma. This approach may offer a new therapeutic avenue for treating this aggressive tumor type.
The study found that HIV-1 Tat protein expression leads to perturbations in the human cellular proteome, affecting gene expression and cellular processes. This has significant implications for understanding HIV-1 latency reversal and potential therapeutic strategies.
Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2. Alteration in transcription and enhancer landscape occurs during disease progression, offering a potent therapeutic mark for targeting cancer cells.
Research reveals ONC201 induces cell death through mitochondrial stress mechanisms, independent of TRAIL transcription. The compound inhibits mitochondrial respiration and reduces DNA copy number, leading to ATP depletion and cell death.
Research findings show that PD-L1 expression facilitates immune escape in medulloblastoma patients. The study identifies subgroup-specific variations in PD-L1 expression and its relationship with therapeutic responses. Immune adjuvant therapies may be necessary to fully realize the benefits of PD-1 blockade treatments.
The study shows that ST1-ADC selectively inhibits tumor cell proliferation and induces tumor cell death in both in vitro and in vivo ovarian cancer models. The data provide promising results for the development of new therapeutic options to treat ovarian cancer.
Researchers developed a quantitative pharmacodynamic assay for detecting apoptosis in fixed tumor tissue, resolving limitations of existing methods. The assay uses colocalization of γH2AX and cleaved caspase-3 markers to identify apoptotic cells with high accuracy.
A peer-reviewed study published in Oncotarget found that OncoDNA's comprehensive testing and analysis services, combining multiple biomarkers, increased oncologists' ability to make informed treatment decisions. The study showed a significant improvement in overall survival for late-stage patients, from six months to over 12 months.
The study reveals a tendency for duplication in the 9p21.3 sequence associated with coronary artery disease, which may affect predisposition to CAD. Sequence analysis shows varied repeats with 10-15 SNPs between each other and 82 SNPs between the human genome sequence.
Precision oncology uses advanced molecular diagnostic technologies to select targeted therapies, resulting in improved overall survival and lower average total healthcare costs. Average weekly costs were significantly lower for the targeted treatment group compared to the control group.
Researchers develop therapeutic antibodies targeting the C-terminus of Sonic hedgehog, a protein involved in tissue homeostasis and repair. These antibodies show promise in inhibiting cancer cell growth and tumor formation in preclinical models.
Research highlights the importance of preserving healthy kidney tissue and minimizing ischemia time in partial nephrectomy to prevent chronic kidney disease. Minimally invasive surgery is also shown to offer therapeutic scope without compromising oncological outcomes.
Researchers found elevated mir-24-3p in breast cancer patients destined to metastasize despite best available therapy. High expression of mir-24-3p correlated with poor survival rate and specific gene expression signature in TCGA.
Researchers propose a new conceptualization of cancer based on physical and biophysical symmetry. The study suggests that understanding cancer through the framework of symmetry can help reveal new ways to understand cancer.